ECP
OACC

Empyrean Capital Partners’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Empyrean Capital Partners’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.56M Hold
900,000
– – 0.31% 85
2025
Q4 		$9.52M Buy
900,000
+150,000
+20% +$1.59M 0.33% 69
2025
Q3 		$7.88M Buy
+750,000
New +$7.84M 0.32% 59

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Empyrean Capital Partners's OACC Position: Q1 2026 in Review

Empyrean Capital Partners held its Oaktree Acquisition Corp III Life Sciences (OACC) position steady in Q1 2026 at 900,000 shares worth $9.56M. The position accounts for 0.31% of the portfolio, ranked #85.

Empyrean Capital Partners first reported a position in OACC in Q3 2025 and has held it in 3 quarters since. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Empyrean Capital Partners held 900,000 shares of Oaktree Acquisition Corp III Life Sciences worth $9.56M as of Q1 2026.
  • Empyrean Capital Partners left its Oaktree Acquisition Corp III Life Sciences share count unchanged in Q1 2026.
  • Oaktree Acquisition Corp III Life Sciences made up 0.31% of Empyrean Capital Partners's portfolio in Q1 2026, its #85 holding.
  • Empyrean Capital Partners first reported a position in Oaktree Acquisition Corp III Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Empyrean Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.